Withdrawal: Makena

Apr. 2023Pharmacy Updates
On March 7, 2023, Covis Pharma announced that it is withdrawing Makena (hydroxyprogesterone caproate injection; also referred to as 17-OHPC) from the market. This drug is used to reduce the risk of preterm birth in women who are pregnant with one baby and have a history of spontaneous preterm birth. Read more about the Makena withdrawal.

Recent Announcements

Register for the Oral Health in Your Pediatric Office CME -accredited webinar

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 10 from noon to 1 p.m. that will provide an overview of oral health in your pediatric office. Providers with a(n) MD/DO, PA, CRNP, RN, or LPN may also apply for topical fluoride certification after completion of this course.
Jun. 2025Education/Webinars

Register for the Oral Health in Your Pediatric Office CME -accredited webinar

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 10 from noon to 1 p.m. that will provide an overview of oral health in your pediatric office. Providers with a(n) MD/DO, PA, CRNP, RN, or LPN may also apply for topical fluoride certification after completion of this course.
Jun. 2025Education/Webinars

CME webinar series: Empowering Providers on Substance Use Disorders

Register for our new CME webinar series: Empowering Providers on Substance Use Disorders
Jun. 2025Education/Webinars